Regenerative osteoarthritis therapy: simple shot reverses cartilage damage in animals
Key Questions
What is the CU Boulder regenerative therapy for osteoarthritis?
The CU Boulder team has developed a repurposed drug combined with a biomaterial patch that fully repairs cartilage damage in animal models within weeks. The project is ARPA-H funded, with clinical trials potentially starting in 18 months.
What recent designation did Enlivex's Allocetra receive for osteoarthritis?
Allocetra, a macrophage reprogramming therapy, received FDA RMAT designation for age-related knee osteoarthritis. It demonstrates age-dependent efficacy, with stronger results observed in patients aged 61 and older.
What is the tetrahedral DNA frame approach for treating osteoarthritis?
It uses a tetrahedral DNA nanostructure to deliver miR-143 directly to joints, demonstrating cartilage protection in a rat OA model. This nucleic acid therapy represents a disease-modifying strategy beyond symptom management.
CU Boulder team develops a repurposed drug and biomaterial patch that fully repairs cartilage in animal models within weeks. ARPA-H funded; clinical trials could start in 18 months. Enlivex's Allocetra (macrophage reprogramming) wins FDA RMAT designation for OA, showing age-dependent efficacy (stronger in 61+). New: Tetrahedral DNA frame delivering miR-143 to joints shows cartilage protection in rat OA model, representing a nucleic acid therapy approach for disease-modifying OA treatment. Offers potential disease-modifying treatment beyond pain management.